Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Revance Therapeutics: Q2 Earnings Insights

Author: Benzinga Insights | August 09, 2022 11:51pm

 

Revance Therapeutics (NASDAQ:RVNC) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM.

Here's what investors need to know about the announcement.

Earnings

Revance Therapeutics missed estimated earnings by 2.33%, reporting an EPS of $-0.88 versus an estimate of $-0.86.

Revenue was up $9.56 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.03 which was followed by a 11.04% drop in the share price the next day.

Here's a look at Revance Therapeutics's past performance:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate -0.91 -1.02 -1.15 -1.05
EPS Actual -0.94 -0.93 -1.10 -1.07
Revenue Estimate 24.01M 24.27M 20.29M 15.48M
Revenue Actual 25.26M 25.95M 19.75M 18.80M

To track all earnings releases for Revance Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Posted In: RVNC

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist